Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$36.75 USD
-2.12 (-5.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $36.70 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNTH 36.75 -2.12(-5.45%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Other News for DNTH
DNTH makes New 52 Week High on September 18
Is DNTH gaining bullish strength? New 52 Week Closing High shows up after advancing 3.76%
Clear Street Initiates Coverage on Dianthus Therapeutics (DNTH) with a 'Buy' Rating | DNTH ...
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc
Dianthus Therapeutics (DNTH) Receives a New Rating from Roth MKM